Systemic Lupus Erythematosus
DNTHDianthus TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for LBL-047 (DNTH212) (BDCA2/TACI Inhibitor) in Systemic Lupus Erythematosus. The expected timing is based on the latest available company guidance and may change.
12/23/25:- First subject dosed; healthy volunteers topline data in H2 2026, indication prioritization update H1 2026. 03/09/26:- Two part Ph1 study ongoing; healthy volunteer data and indication prioritization timelines reiterated for 1H and 2H 2026. 05/05/26:- Indications prioritized: Sjögren's, SLE, dermatomyositis; two-part Ph1 China study ongoing; healthy volunteer data expected 2H 2026. 08/04/26:- DNTH212 Ph1 healthy volunteer data remains expected by Year-End 2026.
Verification
Confirm timing and program details against the company announcement or filing.